Vanda Pharmaceutical’s Nereus may soon break out of its motion sickness niche to become a treatment option for the burgeoning ...

Things have been relatively quiet on the layoff front for the company in 2026, although it was widely reported in June that ...

A U.S. judge has ruled Eli Lilly can keep making marketing claims challenged by Novo pending a ruling on a court case brought ...

As it continues to confront a potential existential threat in the United States, CRDMO juggernaut WuXi AppTec’s finances ...

Pfizer’s Elrexfio has taken another step on its path to potential commercial momentum: The drugmaker just announced another ...

Two late-stage clinical failures of high-value projects have not changed CEO Vas Narasimhan’s projection for Novartis over ...

The new pact will see Regeneron provide doses of the drug—which includes atoltivimab, maftivimab and odesivimab-ebgn—through 2031. In exchange, the company is in line to receive roughly $270 million ...

Eli Lilly has jumped up a ranking of the corporate reputations of diabetes drugmakers, putting it hot on the heels of Novo. | Eli Lilly has jumped up a ranking of the corporate reputations of diabetes ...

Pfizer’s Talzenna is now the first PARP inhibitor approved by the FDA to treat men with metastatic hormone-sensitive prostate ...

As a cornerstone of Merck & Co.’s post-Keytruda oncology strategy, sac-TMT has cleared a clinical milestone. | As a ...

In Panku-Lung01, iza-bren, an EGFRxHER3 ADC, significantly reduced the risk of progression or death by 60% compared with ...

With ivonescimab’s first phase 3 win outside lung cancer and a $2 billion investment from AstraZeneca in its U.S. partner ...